首站-论文投稿智能助手
典型文献
Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy
文献摘要:
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the standard of care for adult acute lymphoblastic leukemia (ALL) patients. In recent years, with the continuous development of immunotherapy, such as chimeric antigen receptor T cells, blinatumomab, and inotuzumab ozogamicin, a series of vital clinical studies have confirmed its high response rate and favorable outcomes for ALL. Although the emergence of immunotherapy has expanded relapsed or refractory (r/r) ALL patients' opportunities to receive allo-HSCT, allo-HSCT is associated with potential challenges. In this review, the role of allo-HSCT in the treatment of adult ALL in the era of immunotherapy will be discussed.
文献关键词:
Acute lymphoblastic leukemia;Allogeneic hematopoietic stem cell transplantation;Immunotherapy;Chimeric antigen receptor-T cells
作者姓名:
Sun Wei;Huang Xiaojun
作者机构:
Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
引用格式:
[1]Sun Wei;Huang Xiaojun-.Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy)[J].中华医学杂志(英文版),2022(08):890-900
A类:
inotuzumab,ozogamicin
B类:
Role,allogeneic,haematopoietic,stem,transplantation,treatment,adult,acute,lymphoblastic,leukaemia,immunotherapy,Allogeneic,hematopoietic,HSCT,currently,standard,care,leukemia,ALL,patients,In,recent,years,continuous,development,such,chimeric,antigen,receptor,cells,blinatumomab,series,vital,clinical,studies,have,confirmed,its,high,response,rate,favorable,outcomes,Although,emergence,has,expanded,relapsed,refractory,opportunities,receive,associated,potential,challenges,this,review,role,will,be,discussed,Acute,Immunotherapy,Chimeric
AB值:
0.529729
相似文献
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai;Meng Wang;Ting Deng;Yuxian Bai;Kai Zang;Zhanhui Miao;Wenlin Gai;Liangzhi Xie;Yi Ba-Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medical Oncology,Henan Cancer Hospital,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Oncology Department,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Sinocelltech Ltd.,Beijing 100176,China;Beijing Engineering Research Center of Protein and Antibody,Beijing 100176,China;Cell Culture Engineering Center,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China
Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy
Shaojie Xu;Yiming Feng;Xingyin Li;Zaozao Huang;Hewei Li;Ganxin Wang-First Clinical College,Huazhong University of Science and Technology,Wuhan 430022,China;Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Yangchunhu Community Hospital,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Department of Orthopedics,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。